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Abstract
Hypoxia is a central problem in tumor treatment because hypoxic cells are less sensitive to chemo- and radiotherapy than
normoxic cells. Radioresistance of hypoxic tumor cells is due to reduced sensitivity towards low Linear Energy Transfer (LET)
radiation. High LET a-emitters are thought to eradicate tumor cells independent of cellular oxygenation. Therefore, the aim
of this study was to demonstrate that cell-bound a-particle emitting 213Bi immunoconjugates kill hypoxic and normoxic
CAL33 tumor cells with identical efficiency. For that purpose CAL33 cells were incubated with 213Bi-anti-EGFR-MAb or
irradiated with photons with a nominal energy of 6 MeV both under hypoxic and normoxic conditions. Oxygenation of cells
was checked via the hypoxia-associated marker HIF-1a. Survival of cells was analysed using the clonogenic assay. Cell
viability was monitored with the WST colorimetric assay. Results were evaluated statistically using a t-test and a Generalized
Linear Mixed Model (GLMM). Survival and viability of CAL33 cells decreased both after incubation with increasing 213Bi-anti-
EGFR-MAb activity concentrations (9.25 kBq/ml–1.48 MBq/ml) and irradiation with increasing doses of photons (0.5–12 Gy).
Following photon irradiation survival and viability of normoxic cells were significantly lower than those of hypoxic cells at all
doses analysed. In contrast, cell death induced by 213Bi-anti-EGFR-MAb turned out to be independent of cellular
oxygenation. These results demonstrate that a-particle emitting 213Bi-immunoconjugates eradicate hypoxic tumor cells as
effective as normoxic cells. Therefore, 213Bi-radioimmunotherapy seems to be an appropriate strategy for treatment of
hypoxic tumors.
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Introduction
In solid tumors hypoxia results from accelerated proliferation
combined with high metabolic activities and poor oxygenation due
to insufficient blood supply [1], [2]. In normoxic tissues the mean
partial pressure of oxygen (p[O2]) is roughly 40 mmHg, while the
p[O2] in hypoxic tumor areas is below ,10 mmHg [3], [4].
Hypoxic cells within a tumor are resistant to radiotherapy, thus
negatively influencing the therapeutic outcome [3]. Radioresis-
tance is supposed to appear at p[O2] ,10 mmHg [4], [5]. It can
be quantified by the oxygen enhancement ratio (OER) expressing
the ratio of radiation dose required under hypoxia and normoxia
to produce the same biological effect [6]. On the one hand, lower
sensitivity towards ionizing radiation is explained by the oxygen
effect [7]. In cells lacking oxygen DNA damage is less severe
because of (i) lower levels of radicals produced by ionizing
radiation that cause indirect DNA strand breaks and (ii) absent
fixation of DNA damage by oxygen [1]. On the other hand,
hypoxia-related tumor radioresistance is triggered by biological
signaling pathways. The hypoxia-inducible transcription factor
HIF-1 modulates more than 100 genes that play a crucial role in
adaption to hypoxia [7], [8]. Moreover, HIF-1 becomes
upregulated after radiation therapy of tumors. HIF-1 induces
cytokines, which are involved in protection of endothelial cells
from the effects of radiation [9]. Altogether, HIF-1 activation leads
to an increased resistance to radio- and chemotherapy, increased
local aggressive growth and an increased risk of metastatic disease
[7], [8].
Previous approaches to overcome radioresistance were aimed at
reducing hypoxia. However, hyperbaric oxygen, red blood cell
transfusion, erythropoiesis-stimulating factors as well as inhalation
of hyperoxic gases with vasodilating drugs did not turn out
satisfactory in clinical settings [10].
Therefore, in recent approaches molecular processes that
trigger radioresistance of hypoxic tumors are exploited in terms
of development of strategies to overcome radioresistance [1]. This
includes compounds that inhibit HIF-1 activity through diverse
molecular mechanisms. For example, the inhibitor of HSP-1
synthesis and stability YC-1 can help to overcome radioresistance
of hypoxic tumour cells [11]. Besides, radiosensitizers like
nitroimidazole derivatives as well as C-1027 and KNK437 have
revealed promising results in terms of enhancement of cytotoxic
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effects of ionizing radiation under hypoxia [1], [12], [13], [14].
The hypoxic cytotoxin tirapazamine showed benefits in patients
with head and neck cancer [15]. Also suicide gene therapy with
the bacterial cytosine deaminase/5-fluorocytosine gene therapy
system under the control of a hypoxia-responsive promoter
significantly enhanced the therapeutic effects of radiotherapy [16].
Another therapeutic strategy involves fractionated irradiation of
hypoxic tumors. As a consequence of radiotherapy tumors become
reoxygenated [9]. Accordingly fractionated irradiation of tumors
was demonstrated to decrease hypoxia [17].
Irradiation of hypoxic tumors with high Linear Energy Transfer
(LET) radiation is an exciting therapeutic option. Because OER
decreases with increasing LET [18] high LET Auger electrons or
a-particles are thought to directly damage DNA and thus to
eradicate tumor cells independent of cellular oxygenation. As
shown recently, hypoxic MCF-7 tumor cells are damaged
selectively and severely by the hypoxia tracer 64Cu-diacetyl-
bis(N(4)-methylthiosemicarbazone) (64Cu-ATSM) due to emission
of Auger electrons [19].
Nevertheless, among high LET-emitters a-particle emitters are
the most promising ones in terms of eradication of tumor cells
independent of cellular oxygenation. Efficacy of targeted tumor
therapy with a-emitters such as 225Ac, 213Bi, 212Bi/212Pb, 211At or
227Th was demonstrated in an increasing number of experimental
and clinical studies [20]. Clinical trials using a-emitter antibody or
peptide conjugates have been conducted in the treatment of
melanoma [21], gliomas [22], [23], acute myeloid leukaemia [24]
and ovarian carcinoma [25].
In a multitude of tumor types, such as head and neck squamous
cell carcinoma (HNSCC) or pancreatic cancer, hypoxia impedes
efficiency of conventional radiation therapy [3]. Because HNSCC
cells are characterized by overexpression of EGFR [26], therapy
with a-emitter immunoconjugates targeting EGFR is a promising
concept. We have compared efficacy of photon irradiation vs.
treatment with 213Bi-anti-EGFR immunoconjugates in CAL33
HNSCC cells under normoxic and hypoxic conditions in order to
prove oxygen-independent cytotoxicity of the a-emitting 213Bi-
anti-EGFR-MAb.
The results of this study indeed show for the first time that
internal irradiation of CAL33 tumor cells with alpha-emitter 213Bi-
anti-EGFR immunoconjugates is equally efficient in eradication of
hypoxic and normoxic cells. Previous work on that subject that has
been carried out some 20 to 40 years ago exclusively used external
sources of irradiation implicating methodical inadequateness.
Therefore 213Bi-radioimmunotherapy could be a promising future
option for treatment of hypoxic tumors.
Materials and Methods
Cell culture
The human head and neck squamous cell carcinoma (HNSCC)
cell line CAL33 was obtained from the Leibniz Institute DSMZ
(German collection of microorganisms and cell cultures). CAL33
cells were shown to over-express EGFR. The cells were grown in
RPMI culture medium (Biochrom, Germany) supplemented with
10% FCS (Biochrom, Germany) and 5% non-essential amino
acids (NEA; Biochrom, Germany) at 37uC in a humidified
atmosphere with 95% air and 5% CO2. These conditions are
referred to as normoxic.
Cultivation of cells under hypoxic conditions
CAL33 cells were seeded in culture flasks or multi-well plates
and allowed to adhere overnight under normoxic conditions. For
adjustment of hypoxia, cells were placed into an air-tight
aluminium chamber at 37uC. From this chamber the air was
evacuated with a vacuum pump and replaced with a mixture of
gas consisting of 95% N2 and 5% CO2 (Fig. 1). After a total of 11
cycles (duration 22 min) of air evacuation and gas-influx the
oxygen concentration in the culture medium was less than 0.66%/
5 mmHg. An oxygen concentration of 1%/10 mmHg was already
reached after 9 min of air evacuation and gas-influx [27], [D.
Schilling, personal communication]. The beginning of air evacu-
ation was referred to time after incubation under hypoxic
conditions.
Detection of the hypoxia marker HIF-1a in CAL33 cells
HIF-1a, found in mammalian cells cultured under reduced
p[O2], is part of the heterodimeric HIF-1 complex. Under
normoxic conditions HIF-1a is rapidly degraded by the ubiqui-
tin-proteasome system [11].
Intensity of HIF-1a expression was checked via Western blot
analysis to indicate the hypoxic status of the CAL33 cells. The
HIF-1a signal was analysed immediately after incubation of
CAL33 cells for different times (0–24 h) under hypoxic conditions.
Because Co2+ induces HIF-1a expression in normoxic cells [28],
CAL33 cells treated with CoCl2 (200 mM, 5 h) were used as
positive control. To determine the kinetics of HIF-1a degradation
in CAL33 cells that were incubated under hypoxic conditions for
3 h, the HIF-1a signal was analysed at different times (0–180 min)
after release from hypoxia and incubation under normoxic
conditions.
For that purpose CAL33 cells were lysed in M-PER buffer
(Thermo Scientific, Pierce Biotechnology, Rockford, IL) in the
Figure 1. Photon irradiation of CAL33 cells in the aluminium
hypoxic chamber. Culture flasks were arranged in three levels,
separated by lead plates (thickness 1.31 cm; distance 6.5 cm). Thus,
irradiation doses were reduced by half (D1, D1/2, D1/4), respectively, as
confirmed by dosimetric measurements. Cells were irradiated with
three different doses in one irradiation experiment. Hypoxia was
established by repeated aspiration of air and influx of 95% N2, 5% CO2.
doi:10.1371/journal.pone.0064730.g001
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presence of protease inhibitors (Complete Mini Protease Inhibitor,
Roche, Switzerland). Cell debris was pelleted by centrifugation
and protein supernatants were concentrated. Protein concentra-
tions were determined according to the method of Bradford
(BioRad, Germany). Cell lysates (47.5 mg protein per lane) were
subjected to SDS-PAGE (8% acrylamide) and subsequently
blotted onto a PVDF membrane. For detection of HIF-1a, the
membrane was probed with primary (monoclonal anti-human
HIF-1-a IgG1 from mouse, BD Biosciences) and secondary (Fc-
specific goat anti-mouse IgG coupled with alkaline phosphatase,
Sigma) antibodies. HIF-1-a was visualized in a colour reaction
using NBT and BCIP as substrates (Fig. 2).
Coupling of the a-emitter 213Bi to the anti-EGFR-MAb
matuzumab
Matuzumab (Merck, Germany) was conjugated with the
bifunctional chelating agent N-[2-amino-3-(p-isothiocyanatophe-
nyl)propyl1]-trans-cyclohexane-1,2-diamine-N,N’,N’’,N’’’,N’’’’-
pentaacetic acid (CHXA’’-DTPA) (Macrocyclics, USA) as previ-
ously described [29]. The a-emitter 213Bi was eluted from an
225Ac/213Bi generator system produced by the Institute for
Transuranium Elements (European Commission, JRC, Germany)
[30]. Chelated anti-EGFR-mAb (100 mg) was incubated with the
213Bi eluate (BiI4
-/BiI5
2- anionic species) in 0.4 M ammonium
acetate buffer at pH 5.3 for 7 min. Unbound 213Bi ions were
cleared from 213Bi-anti-EGFR-Mab immunoconjugates by size-
exclusion chromatography (PD-10 columns, GE Healthcare,
Germany). Purity of 213Bi-immunoconjugates was assayed via
instant thin-layer chromatography [31]. Binding of 213Bi-anti-
EGFR-MAb to CAL33 cells was quantified as previously
described [32].
Irradiation of CAL33 cells with 213Bi-anti-EGFR-MAb under
normoxic and hypoxic conditions
CAL33 cells were seeded in 96-well plates (16104 cells per well)
or 24-well plates (200 cells per well) for use in cell viability assays or
clonogenic assays, respectively. For adjustment of cell metabolism
to hypoxia, CAL33 cells were incubated in the aluminium
chamber under hypoxic conditions for 3 hours before irradiation.
213Bi-anti-EGFR-MAb (9.25 kBq–1.48 MBq) was added within
10 min after removal of cells from the aluminium chamber.
Subsequently, cells were again incubated under hypoxic conditions
for 3 hours. Cells were then kept under normoxic conditions until
evaluation of viability and survival. Treatment of CAL33 cells with
213Bi-anti-EGFR-MAb under normoxic conditions was done in an
analog setting.
Irradiation of CAL33 cells with linear accelerator photons
under normoxic and hypoxic conditions
CAL33 cells (4.56106) were seeded in 25 cm2 culture flasks.
Culture flasks were incubated in the aluminium chamber under
hypoxic conditions for 3 hours. Subsequently hypoxic cells inside
the chamber were irradiated from outside with photons from a
linear accelerator (Varian Clinac DHX) with various doses
ranging from 0.5–12 Gy (nominal photon energy 6 MeV) as
shown in Fig. 1. After irradiation cells were kept inside the
aluminium chamber under hypoxic conditions for further 3 hours.
CAL33 cells kept under normoxic conditions were irradiated with
photons also in the aluminium chamber (under normoxic
conditions). After irradiation and 3 h incubation under hypoxic
or normoxic conditions, cells were detached, seeded in 96-well
plates (16104 cells per well) or 24-well plates (100 cells per well)
and incubated under normoxic conditions until evaluation of cell
viability/survival.
Cell viability assay and clonogenic assay
For colorimetric determination of cell viability/metabolic
activity, CAL33 cells were incubated with the water-soluble
tetrazolium salt 1 (WST-1, Roche, Germany). The rate of WST-1
cleavage to a formazan dye by mitochondrial dehydrogenases
correlates with the number of viable cells. Formation of the
formazan dye was quantified with a scanning multi-well spectro-
photometer (ELISA reader, BioTek, USA). 3.5 days after
treatment of cells in 96-well plates, culture medium was replaced
with 100 ml of fresh culture medium and 10 ml of WST-1 was
added. Absorbance was measured at 440 nm 1.5 h later.
Cell survival was determined using the clonogenic assay. For
that purpose cells were seeded in 24-well plates and the number of
cell clones consisting of more than 50 cells was counted
microscopically 4.5 days after treatment of cells.
Statistical analysis
Statistical analysis was performed using the statistical software
program R, version 2.12.2 (R Foundation for Statistical Comput-
ing, Vienna, Austria). All statistical analyses are based on at least 5
independent experiments. To compare the results of the different
experiments, a t-test according to Welsh and a parameter test on
b=0 in a Generalized Linear Mixed Model (GLMM) were used.
The t-test evaluates whether the means of cell survival and cell
viability under normoxia and hypoxia differ significantly. For the
comparison of controls an analysis of variance (ANOVA) was
conducted additionally. The GLMM takes into account different
conditions that could occur during independent experiments by
inclusion of the experiment number as random effect. The
exponential function of the model parameter for oxygenation can
Figure 2. Western blot analysis of HIF-1a expression in CAL33
cells under normoxia and hypoxia. A) HIF-1a expression at
different times (0–24 h) after setup of hypoxia; 3 h+3 h: incubation of
cells done twice for 3 hours under hypoxia, interrupted by a 10 min
phase under normoxic conditions. B) HIF-1a expression at different
times (0–180 min) after release of CAL33 from hypoxia and incubation
under normoxic conditions; control: normoxic cells; CoCl2: cells treated
with CoCl2 used as positive control; 160 K, 105 K, 75 K molecular
weight markers (RPN800, GE Healthcare). Unspecific staining of protein
bands other than HIF-1a was used as sample loading control.
doi:10.1371/journal.pone.0064730.g002
213Bi-Anti-EGFR-MAb Kills Hypoxic Cells
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64730
be interpreted as relative risk factor (RR), denoting exp(b)-/RR-
fold higher survival for normoxia than for hypoxia. The level of
significance was set to a=0.05.
Results
HIF-1a expression in CAL33 cells under normoxic and
hypoxic conditions
To monitor the hypoxic status of CAL33 cells, expression of
HIF-1a was analysed via western blotting. HIF-1a could be
detected for the first time 30 min after incubation of CAL33 cells
under hypoxic conditions and reached a maximum after 3 hours
(Fig. 2A). Cells were also truly hypoxic after 6 hours under
hypoxia (Fig. 2A, 6 h) and after incubation done twice for 3 hours
under hypoxia, interrupted by a 10 min phase under normoxic
conditions (Fig. 2A, 3 h+3 h). The 6 h period and the 3 h+3 h
period represent times under hypoxia of CAL33 cells irradiated
with photons and incubated with 213Bi-anti-EGFR-MAb, respec-
tively. After 24 hours under hypoxia, cells had died and HIF-1a
could no longer be detected (Fig. 2A, 24 h).
In CAL33 cells that had been incubated under hypoxic
conditions for 3 hours, release from hypoxia and cultivation
under normoxic conditions resulted in a decrease of the HIF-1a
signal. The HIF-1a signal could still be detected 15 min after
release from hypoxia. After 30 min HIF-1a had almost disap-
peared (Fig. 2B).
Survival and viability of CAL33 cells after incubation
under hypoxic conditions
To evaluate the consequences of hypoxia on survival and
viability, CAL33 cells were incubated under hypoxia correspond-
ing to the treatment protocols. Survival and viability of the cells
were compared with cells kept under normoxia. No significant
difference with respect to cell survival (clonogenic assay) could be
observed between normoxic cells and cells transiently kept under
hypoxic conditions in almost all statistical evaluations. Regarding
the WST assay statistical tests indicated significantly lower cell
viability of hypoxic cells.
Survival of CAL33 cells after irradiation with photons or
with 213Bi-anti-EGFR-MAb under normoxia and hypoxia
The number of CAL33 cell clones decreased with increasing
dose of photons, both under normoxic and hypoxic conditions.
However, at every dose, survival of CAL33 cells incubated under
hypoxic conditions was significantly higher than survival of cells
incubated under normoxic conditions. After irradiation with 12
Gy the mean number of clones amounted to 0.1 (standard
deviation SD=0.3) for normoxic cells and to 12.3 (SD=5.8) for
hypoxic cells (Fig. 3A). This clearly demonstrates that hypoxic cells
are less sensitive towards photon irradiation than normoxic cells.
Incubation of CAL33 cells with 213Bi-anti-EGFR-MAb resulted
in an excellent binding of immunoconjugates (78.3%, SD=8.0), as
a prerequisite for high cytotoxicity. Corresponding to photon
irradiation, the number of CAL33 cell clones decreased with
increasing 213Bi-anti-EGFR-MAb activity concentration both for
cells irradiated under hypoxic and normoxic conditions. In
contrast to photon irradiation the number of cell clones did not
differ significantly for cells irradiated under normoxic or hypoxic
conditions at any given activity concentration. For example, at
activity concentrations of 9.25 kBq/ml and 74 kBq/ml the mean
number of clones accounted for 83.3 (SD=19.8) and 5.3
(SD=3.1) under normoxia, as well as 85.8 (SD=23.6) and 5.8
(SD=4.2) under hypoxia, respectively. After incubation with
370 kBq/ml 213Bi-anti-EGFR-MAb none of the cells survived
both under normoxia and under hypoxia (mean= 0; SD=0)
(Fig. 3A). This indicates that targeted treatment with the a-emitter
213Bi eradicates normoxic and hypoxic cells with identical
efficiency.
Viability of CAL33 cells after irradiation with photons or
with 213Bi-anti-EGFR-MAb under normoxia and hypoxia
Viability of CAL33 cells was determined using the WST assay.
Cell viability decreased with increasing doses of photon irradia-
tion. CAL33 cells treated under hypoxia showed superior viability
compared to cells irradiated under normoxia (Fig. 3B). For
example, absorbance after irradiation with 3, 6 and 12 Gy was
0.73 (SD=0.10), 0.44 (SD=0.06) and 0.29 (SD=0.05) for
normoxic cells and 0.89 (SD=0.19), 0.67 (SD=0.10) and 0.40
(SD=0.06) for hypoxic cells, respectively. This is in accordance
with the results of the clonogenic assay.
After incubation with increasing activity concentrations of 213Bi-
anti-EGFR-MAb (37 to 370 kBq/ml), cell viability progressively
decreased. At an activity concentration of 370 kBq/ml nearly all
cells had been eradicated. Only due to remaining cell-debris the
absorbance did not decrease to zero but remained at 0.3 to 0.4 for
lethal activity concentrations ranging from 370 kBq/ml to
1.48 MBq/ml of 213Bi-anti-EGFR-MAb. Cell viability was affect-
ed identically in hypoxic and normoxic cells (Fig. 3B). Again, these
results are in contrast to the effects of photon irradiation and are in
accordance with those of the clonogenic assay after 213Bi-anti-
EGFR-MAb irradiation.
Oxygen enhancement ratios (OER) for survival and
viability of CAL33 cells
The OER is defined as the ratio of radiation doses required to
produce the same biological effect in cells kept under hypoxia and
normoxia. As deduced from the data presented in Fig. 3, the OER
for cell survival varied between 1.5 and 1.9 (mean 1.7; SD=0.1).
Accordingly, the OER for cell viability varied between 1.6 and 2.3
(mean 1.8; SD=0.2). In contrast, after irradiation with 213Bi-anti-
EGFR-MAb under hypoxic and normoxic conditions both
survival and viability did not differ significantly as expressed by
OER values of 1, respectively (data not shown).
Statistical evaluation of irradiation effects under
normoxic and hypoxic conditions with regard to overall
survival and viability of CAL33 cells
With regard to overall survival of CAL33 cells after photon
irradiation both statistical methods revealed that the number of
clones after irradiation under hypoxia was significantly higher
compared to irradiation under normoxia (GLMM: p= 0.000; t-
test: p = 0.000; data not shown). According to the GLMM the
relative risk (RR) was 1.28 (Fig. 4). In contrast, overall survival of
CAL33 cells after irradiation with 213Bi-anti-EGFR-MAb under
hypoxic and normoxic conditions did not differ significantly in the
GLMM with a RR of 1.07 (p= 0.547) (Fig. 4). Evaluation of the
results with the t-test confirmed that there is no difference between
hypoxia and normoxia (p = 0.547; data not shown).
Statistical analyses of the results of the WST viability assay were
in accordance with those of the clonogenic assay. Overall cell
viability was significantly higher after photon irradiation under
hypoxic conditions compared to normoxic conditions with a RR
of 1.08 (p = 0.000), according to the GLMM and confirmed by the
t-test (p = 0.000; data not shown) (Fig. 4). Moreover, irradiation of
CAL33 cells with 213Bi-anti-EGFR-MAb under hypoxic and
normoxic conditions did not result in a statistically significant
213Bi-Anti-EGFR-MAb Kills Hypoxic Cells
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difference concerning overall cell viability, both according to the
GLMM (RR=1.00; p = 0.950) and to the t-test (p = 0.933; data
not shown) (Fig. 4).
Statistical evaluation of irradiation effects under
normoxic and hypoxic conditions with regard to survival
and viability of CAL33 cells at different doses/activity
concentrations
The GLMM data from the clonogenic assays revealed that
survival of CAL33 cells after photon irradiation under hypoxic
conditions was significantly higher than under normoxic condi-
tions at each dose analysed. Moreover, the RR increased with
increasing doses, i.e. from 1.07 at 0.5 Gy, to 12.24 at 12 Gy. After
irradiation with 213Bi-anti-EGFR-MAb, cell survival was not
significantly different under hypoxia or normoxia at any given
activity concentration (Fig. 5A).
The results obtained from the clonogenic assay could be
confirmed with the GLMM data from the WST cell viability assay.
After photon irradiation under hypoxic conditions metabolic
activity of CAL33 cells was significantly higher than after
irradiation under normoxic conditions at each dose analysed.
The maximum RR was observed at 6 Gy (1.15). At 12 Gy the RR
was 1.08. In contrast, after irradiation of cells with 213Bi-anti-
EGFR-MAb, cell viability was not significantly different at any
activity concentration investigated in terms of irradiation effects
under hypoxia and normoxia (Fig. 5B).
Discussion
Hypoxic areas within solid tumors are still a major problem in
cancer treatment. There are obvious connections between hypoxia
and (i) resistance towards radiation therapy and chemotherapy, (ii)
acquirement of invasive and metastatic properties and (iii) a poor
Figure 3. Clonogenic survival and viability of normoxic and hypoxic cells after irradiation with photons or 213Bi-anti-EGFR-MAb.
Results of single experiments are shown as pale coloured graphs, results of means as bold coloured graphs. A) Number of clones (clonogenic assay)
and B) absorbance (WST viability assay) as a function of activity concentration (213Bi-anti-EGFR-MAb) or photon dose, respectively.
doi:10.1371/journal.pone.0064730.g003
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clinical prognosis [33]. Hypoxia triggers radioresistance by two
different ways. As cellular oxygen concentration decreases, i.e. as
hypoxia increases, radiosensitivity of tumor cells decreases
accordingly, a phenomenon that was termed the oxygen effect
[18]. This is obviously due to a reduced formation of radicals
finally causing DNA damage, being strictly dependent on oxygen
supply. Furthermore, the duration of hypoxia influences radio-
sensitivity of tumor cells [34]. Thus the second way how hypoxia
triggers radioresistance is due to physiological changes of hypoxic
tumor cells. As a consequence of reduced p[O2] levels, hypoxia
inducible factors (HIFs) modulate cellular processes via regulation
of transcription, which finally affect radioresistance towards
photon irradiation [6], [7], [11]. This implicates that hypoxia
induced radioresistance is dependent on adjustment of cell
metabolism to hypoxic conditions. To accommodate this fact,
CAL33 cells were incubated for 3 hours under hypoxia before
irradiation. As we have demonstrated, HIF-1a appeared 30 min
after incubation of CAL33 cells under hypoxia and reached
maximum expression after 3 h. Moreover, HIF-1a could be
detected at any time of irradiation of CAL33 cells under hypoxia,
thus ensuring the hypoxic status (Fig. 2). In addition, oxygen
pressure in the culture medium was ,10 mmHg 9 min after onset
of hypoxic conditions. Assuming that reduced radiosensitivity due
to hypoxia appears at p[O2] ,10 mmHg [4], [5], during a
180 min incubation with 213Bi-anti-EGFR-MAb, 213Bi acts on
truly hypoxic cells for a period of 171 min (180 min minus 9 min).
This corresponds to 80.7% of the applied 213Bi activity
(tK=46 min). Again this demonstrates that the protocols used
for irradiation of CAL33 cells under hypoxic conditions were
adequate and that cells were truly hypoxic at the time of
irradiation.
The results of statistical analysis revealed that both survival and
viability of hypoxic CAL33 cells after photon irradiation were
significantly higher compared to normoxic cells (Fig. 4). For cell
survival, the oxygen enhancement ratio (OER) varied between 1.5
and 1.9 (mean 1.7; SD=0.1). Accordingly, the OER for cell
viability varied between 1.6 and 2.3 (mean 1.8; SD=0.2) (data not
shown). These results are in accordance with previously published
OER values [18]. In contrast, both survival and viability after
irradiation with 213Bi-anti-EGFR-MAb under hypoxic and
normoxic conditions did not differ significantly (Fig. 4). The
OER was 1, respectively, confirming that there is no difference
with regard to cytotoxicity (data not shown). This again
demonstrates efficacy of alpha-emitters in terms of eradication of
hypoxic cells.
The impact of incubation of CAL33 cells under hypoxic
conditions turned out to be negligible in terms of survival.
Incubation of cells under hypoxia – without irradiation – did not
decrease clonogenic survival, measured 4.5 days after hypoxia,
compared to cells that were grown under normoxia throughout.
However, analysis of cell viability 3.5 days after hypoxia showed
slightly higher viability of normoxic cells, indicating that hypoxia
might have caused enduring changes in cell metabolism. Also the
RR for cell viability was less than the RR for cell survival (Figs. 4,
5). The different results can be due to the different times of
measurement for cell viability and cell survival or most likely, due
to the different end-points that are determined by the different
assays. Nevertheless, these results are not contradictory to the
oxygen independent eradication of CAL33 by 213Bi-anti-EGFR-
MAb.
The RR for both cell survival and cell viability increased with
increasing doses of photon irradiation. For cell survival the RR
increased from 1.07 at 0.5 Gy, to 12.24 at 12 Gy (Fig. 5A). This
indicates that the effect of radioresistance on survival of hypoxic
tumor cells increases with increasing doses of photon irradiation.
This is assumed to be due to the mechanism of DNA-damage
induction after photon irradiation. In the presence of oxygen
(normoxia) radiation induced formation of radicals that finally
cause DNA-damage increases with increasing doses. In the
absence of oxygen, formation of radicals is limited even at high
irradiation doses. The maximum RR for cell viability was
observed already at 6 Gy (RR=1.15). At 12 Gy the RR was
1.08. This is due to the converging graphs of Fig. 3B. For
normoxia the minimum of absorbance was already reached at 6
Gy. Thus, the difference between normoxia and hypoxia gradually
decreased between 6 and 12 Gy.
In contrast, after irradiation with 213Bi-anti-EGFR-MAb cell
survival and viability were not significantly different under hypoxia
and normoxia at any activity concentration investigated (Fig. 5).
This demonstrates that the effect of alpha-particle radiation is
independent of free radical formation. Densely ionizing, high LET
alpha-particle radiation directly produces DNA double-strand
breaks with high efficiency, thus causing multiple breaks within
single chromosomes independent of cellular oxygenation. There-
fore, alpha-particles emitted by 213Bi immunoconjugates can
overcome the oxygen enhancement effect as observed for photon
irradiation in CAL33 cells.
This characteristic of the alpha-emitter 213Bi could possibly be
exploited in cancer treatment. Hypoxic regions within solid tumors
are associated with increased resistance to radiation and chemo-
therapy and therefore are considered as a negative prognostic
factor in various types of cancer [4], [35]. Therefore, new
therapeutic options specifically addressing treatment of hypoxic
tumor areas are needed.
Cytotoxicity of irradiation of hypoxic cells with alpha-emitters
such as 210Po and 238Pu from an external source in comparison to
low LET emitters has been evaluated in previous studies, for
example by Jenner et al. [36] and by the group of Barendsen [37].
It could be demonstrated that the OER decreases with increasing
Figure 4. Relative risk for cell survival/viability after irradiation
with photons/213Bi-anti-EGFR-MAb under normoxia/hypoxia.
Relative risk (RR) (&) denotes RR-fold higher survival of CAL33 cells
irradiated under hypoxia compared to normoxia. RR was calculated
according to the Generalized Linear Mixed Model (GLMM). Overall cell
survival/viability is significantly (RR-fold) higher under hypoxia, if the
95%- confidence interval (N) doesn’t include the value 1 (red line).
doi:10.1371/journal.pone.0064730.g004
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LET of the applied radiation. The results of these studies suggested
that application of high LET alpha-particles seems promising in
therapy of hypoxic tumors. However, the external irradiation
studies suffer from methodical inadequateness. For external
irradiation with alpha-emitters under hypoxic conditions cells
had to be seeded on ultrathin foils. This resulted in (i) oxygen
influx [38], (ii) inhomogeneous dose distribution and (iii) an
insufficient irradiation of the whole cell [39]. Consequently OER
findings varied considerably as shown in the work of Wenzl and
Wilkens [18]. Moreover, these studies did not consider ways of
application of alpha-emitters to tumors, neglecting that external
irradiation of tumors with alpha-emitters is not applicable.
EGRF is a promising receptor in targeted therapy because it is
overexpressed in a variety of tumors such as bladder cancer [40] as
well as head and neck cancer [41]. In fact, application of the anti-
EGFR antibody cetuximab turned out beneficial in treatment of
patients suffering from colorectal cancers and HNSCC [41].
However, because resistances towards anti-EGFR therapy were
shown to develop in tumors, particularly in those with high EGFR
expression [26], coupling of cytotoxic compounds to the antibodies
is a promising strategy to overcome resistances. Therefore,
coupling of compounds that efficiently eradicate hypoxic tumor
cells, such as a-particle emitting radionuclides, seems a promising
strategy. As we have demonstrated in vitro, the a-emitter 213Bi
coupled to the anti-EGFR antibody matuzumab efficiently kills
hypoxic tumor cells. However, targeting of hypoxic tissue in vivo
with 213Bi-anti-EGFR antibody conjugates could be impaired due
to the poorly vascularized microenvironment of hypoxic tumors
Figure 5. Relative risk for cell survival (A)/viability (B) at different photon doses/213Bi-anti-EGFR-MAb activity concentrations under
normoxia/hypoxia. Relative risk (RR) (&) denotes RR-fold higher survival of CAL33 cells irradiated under hypoxia compared to normoxia. RR was
calculated according to the Generalized Linear Mixed Model (GLMM). Overall cell survival/viability is significantly (RR-fold) higher under hypoxia, if the
95%- confidence interval (N) doesn’t include the value 1 (red line).
doi:10.1371/journal.pone.0064730.g005
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[33]. Targeting of hypoxic tissues in vivo could be improved by
application of smaller carrier molecules that show a better tissue
penetration than antibodies. This could include Fab fragments of
anti-EGFR antibodies and single chain antibodies (scFv) efficiently
targeting EGFR.
Moreover, targeting of hypoxic tumor cells with the a-emitter
213Bi could possibly be achieved independently of EGFR
targeting. For that purpose drugs that preferentially target hypoxic
tumor cells should be modified in such a way that they can be
labeled with the a-emitter 213Bi. Among the dithiosemicarbazone
compounds the hypoxia-selective agent diacetyl-bis(N(4)-
methylthiosemicarbazone) labeled with the high LET Auger-
emitter 64Cu (64Cu-ATSM) was already shown to increase DNA-
damage and cytotoxicity in hypoxic cells [19]. Furthermore,
labeling of misonidazole (MISO) and azomycinarabinofuranoside
(AZA) of the nitroimidazole family of radiotracers with a-emitters
via appropriate chelating agents could be a promising therapeutic
strategy. Both MISO and AZA labeled with the PET tracer 18F (F-
MISO; FAZA) were successfully evaluated in clinical studies in
terms of detection of hypoxic tumors [42]. In summary, targeting
of hypoxic tumor cells with a-particle emitting radionuclides is a
promising strategy to overcome resistance towards photon
irradiation and to improve efficacy of treatment of hypoxic
tumors.
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